Cargando…
Head and Neck Sarcomas: A Comprehensive Cancer Center Experience
Head/neck sarcomas are rare, accounting for about 1% of head/neck malignancies and 5% of sarcomas. Outcomes have historically been worse in this group, due to anatomic constraints leading to difficulty in completely excising tumors, with high rates of local recurrence. We retrospectively analyzed ca...
Autores principales: | Tejani, Mohamedtaki A., Galloway, Thomas J., Lango, Miriam, Ridge, John A., von Mehren, Margaret |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3795370/ https://www.ncbi.nlm.nih.gov/pubmed/24202325 http://dx.doi.org/10.3390/cancers5030890 |
Ejemplares similares
-
The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer
por: Tejani, Mohamedtaki A, et al.
Publicado: (2010) -
Head and neck surgery recommendations during the COVID-19 pandemic
por: Galloway, Thomas J, et al.
Publicado: (2020) -
Real-world clinical effectiveness of sorafenib among patients with unresectable hepatocellular carcinoma at two centers in the United States
por: Li, Daneng, et al.
Publicado: (2023) -
Phospho-(T356)RB1 predicts survival in HPV-negative squamous cell carcinoma of the head and neck
por: Beck, Tim N., et al.
Publicado: (2015) -
New drugs and combinations for the treatment of soft-tissue sarcoma: a review
por: Somaiah, Neeta, et al.
Publicado: (2012)